文献速递前列腺癌

DNA修复基因胚系突变与局限性前列腺癌的关联

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
PubMed 文献 · Eur Urol · 2021-10-25

这项横断面研究在学术生物样本库中分析了1588例局限性前列腺癌患者和3273名无癌男性的17个DNA修复基因突变率。非洲裔患者突变率低于欧洲裔(1.4% vs 4.0%,p=0.02),仅BRCA2在歐洲裔中显著富集(1.0% vs 0.28%,p=0.03)。高风险和极高风险患者中分别有3.7%和6.2%携带任何胚系突变。

要点

  • 局限性前列腺癌患者DNA修复基因胚系突变率低,非洲裔更低。
  • 仅BRCA2突变在欧洲裔中显著富集。
  • 高风险特征增加胚系DNA修复突变可能性。

核心结论

  • 局限性前列腺癌患者中DNA修复基因胚系突变率低,尤其非洲裔人群。
  • 仅高风险、极高风险及淋巴结阳性患者中突变率超过2.5%。
  • 风险分层对筛选胚系基因检测适宜人群很重要。

研究设计与样本

  • 横断面研究,纳入2391例局限性前列腺癌患者,其中1588例进行了17个DNA修复基因突变分析。
  • 对照包括3273名无癌男性及gnomAD男性。
  • 按遗传祖先(欧洲裔和非洲裔)进行负荷检验。

主要发现

  • 非洲裔局限性前列腺癌患者DNA修复基因突变率低于欧洲裔(1.4% vs 4.0%,p=0.02)。
  • 欧洲裔患者突变率与生物样本库对照(4.0% vs 2.8%,p=0.15)及gnomAD对照(4.0% vs 3.1%,p=0.04)比较。
  • 非洲裔患者突变率与生物样本库对照(1.4% vs 1.8%,p=0.8)及gnomAD对照(1.4% vs 2.1%,p=0.5)比较。
  • 仅BRCA2突变在欧洲裔中较gnomAD对照显著富集(1.0% vs 0.28%,p=0.03)。
  • 高风险和极高风险患者中分别有3.7%和6.2%携带任何胚系突变,1.0%和2.5%携带BRCA2突变。

关键数值与推荐

  • 高风险标准:21%患者符合;极高风险标准:11%患者符合。
  • 高风险患者中任何胚系突变率3.7%,BRCA2突变率1.0%。
  • 极高风险患者中任何胚系突变率6.2%,BRCA2突变率2.5%。

临床怎么用

  • 局限性前列腺癌患者中常规胚系检测收益低,应优先高风险人群。
  • 非洲裔局限性前列腺癌患者胚系突变率更低,检测前需结合风险分层。

局限性

  • 研究为单中心、相对小样本的队列分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identification of germline mutations in DNA repair genes has significant implications for the personalized treatment of individuals with prostate cancer (PrCa). OBJECTIVE: To determine DNA repair genes associated with localized PrCa in a diverse academic biobank and to determine genetic testing burden. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study of 2391 localized PrCa patients was carried out. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Genetic ancestry and mutation rates (excluding somatic interference) in 17 DNA repair genes were determined in 1588 localized PrCa patients and 3273 cancer-free males. Burden testing within individuals of genetically determined European (EUR) and African (AFR) ancestry was performed between biobank PrCa cases and cancer-free biobank and gnomAD males. RESULTS AND LIMITATIONS: AFR individuals with localized PrCa had lower DNA repair gene mutation rates than EUR individuals (1.4% vs 4.0%, p = 0.02). Mutation rates in localized PrCa patients were similar to those in biobank and gnomAD controls (EUR: 4.0% vs 2.8%, p = 0.15, vs 3.1%, p = 0.04; AFR: 1.4% vs 1.8%, p = 0.8, vs 2.1%, p = 0.5). Gene-based rare variant association testing revealed that only BRCA2 mutations were significantly enriched compared with gnomAD controls of EUR ancestry (1.0% vs 0.28%, p = 0.03). Of the participants, 21% and 11% met high-risk and very-high-risk criteria; of them, 3.7% and 6.2% had any germline genetic mutation and 1.0% and 2.5% had a BRCA2 mutation, respectively. Limitations of this study include an analysis of a relatively small, single-institution cohort. CONCLUSIONS: DNA repair gene germline mutation rates are low in an academic biobank cohort of localized PrCa patients, particularly among individuals of AFR genetic ancestry. Mutation rates in genes with published evidence of association with PrCa exceed 2.5% only in high-risk, very-high-risk localized, and node-positive PrCa patients. These findings highlight the importance of risk stratification in localized PrCa patients to identify appropriate patients for germline genetic testing. PATIENT SUMMARY: In the majority of patients who develop localized prostate cancer, germline genetic testing is unlikely to reveal an inherited DNA repair mutation, regardless of race. High-risk features increase the possibility of a germline DNA repair mutation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lee DJ, Hausler R, Le AN, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol. 2021. PMID: 34711450. doi:10.1016/j.eururo.2021.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。